Latest News and Press Releases

Vedtægter for Novo Nordisk A/S 2026 Vedhæftet fil AOA260326-NN Vedtægter 2026 ...

Articles of Association for Novo Nordisk A/S 2026 Attachment AOA260326-NN Articles of Association 2026 ...

FDA has approved Awiqli® injection 700 units/mL, the first and only once-weekly, long-acting basal insulin as an adjunct to diet and exercise to improve ..

Bagsværd, Denmark, 26 March 2026 – Today, Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Lars Rebien Sørensen, chair of the Board of Directors, stated:“2025 was a...

In a phase 2 trial in Chinese people with T2D, UBT251 showed a mean HbA1c reduction of up to 2.16%, and a mean weight reduction of up to of up to 9.8% ...

Bagsværd, Denmark, 23 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...

US FDA has approved Wegovy® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term.

Bagsværd, Denmark, 16 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...

Bagsværd, Denmark, 9 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...

Bagsværd, Denmark, 2 March 2026 – The employees in Novo Nordisk A/S have completed the election of employee representatives to the Board of Directors of Novo Nordisk A/S. The following employee...